Disulfide bond disrupting agents activate the unfolded protein response in EGFR- and HER2-positive breast tumor cells

Many breast cancer deaths result from tumors acquiring resistance to available therapies. Thus, new therapeutic agents are needed for targeting drug-resistant breast cancers. Drug-refractory breast cancers include HER2+ tumors that have acquired resistance to HER2-targeted antibodies and kinase inhi...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferreira, Renan B., Wang, Mengxiong, Law, Mary E., Davis, Bradley J., Bartley, Ashton N., Higgins, Paul J., Kilberg, Michael S., Santostefano, Katherine E., Terada, Naohiro, Heldermon, Coy D., Castellano, Ronald K., Law, Brian K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5438706/
https://www.ncbi.nlm.nih.gov/pubmed/28423644
http://dx.doi.org/10.18632/oncotarget.15952

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5438706/
https://www.ncbi.nlm.nih.gov/pubmed/28423644
http://dx.doi.org/10.18632/oncotarget.15952

Ejemplares similares